Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

AI Briefing

• – New data from the AP-101-02 Phase 2 trial show clinically meaningful disease modification and prolonged survival in ALS patients.
• – The AP-101 lead program demonstrates efficacy as an ALS treatment with improved clinical outcomes.
• – AL-S Pharma to present additional AP-101 data at an upcoming medical conference.